Sign in Subscribe

msi-h

A collection of 131 issues

MSI-H/dMMR prevalence varies by age and sex in Japanese cancer cohort

Skip to content The CRC Digest ◇ RESEARCH MSI-H/dMMR prevalence varies by age and sex in Japanese cancer cohort Study of 1,130 older patients (median age 78) with gastric, colorectal, and endometrial cancers characterized deficient mismatch repair protein expression patterns, informing immunotherapy eligibility in aging populations. (Jpn J Clin

Early-onset CRC shows distinct genomic landscape in dual-cohort analysis

Skip to content The CRC Digest ◇ RESEARCH Early-onset CRC shows distinct genomic landscape in dual-cohort analysis Analysis of TCGA PanCancer Atlas and MSK-IMPACT 50K cohorts reveals reproducible mutational differences in colorectal cancer diagnosed before age 50, with implications for biomarker-driven treatment. (PLoS One) This content is informational only and does

CRC Research Update — October 01, 2026

Today's colorectal cancer research highlights

Case Report Describes Delayed, Multisystem Immune Side Effects After Nivolumab Plus Ipilimumab

Skip to content The CRC Digest ♥ LIVING WITH CRC Case Report Describes Delayed, Multisystem Immune Side Effects After Nivolumab Plus Ipilimumab A patient with MSI-high colon cancer developed adrenocorticotropic hormone deficiency during combination immunotherapy and, six months after the final nivolumab dose, presented with bilateral knee arthritis and elevated hepatobiliary

CRC Research Update — September 27, 2026

Today's colorectal cancer research highlights

CRC Research Update — September 25, 2026

Today's colorectal cancer research highlights

MSI-high CRC with NTRK fusion achieved complete response with FOLFOX-bevacizumab after immunotherapy failure

Skip to content The CRC Digest MSI-high CRC with NTRK fusion achieved complete response with FOLFOX-bevacizumab after immunotherapy failure A 63-year-old woman experienced tumor progression on pembrolizumab but achieved a complete response sustained over three years with second-line chemotherapy. (International Cancer Conference Journal) This content is informational only and does

CRC Research Update — September 24, 2026

Today's colorectal cancer research highlights

RNF43 mutation linked to immune evasion in MSI-high colorectal cancer

Skip to content The CRC Digest ◇ RESEARCH RNF43 mutation linked to immune evasion in MSI-high colorectal cancer The RNF43 p.G659fs mutation, found in 8% of colorectal cancers and enriched in MSI-H tumors, promotes natural killer cell dysfunction through PI3K/AKT/mTOR signaling and HLA-E up-regulation. (Sci Adv) This content

CRC Research Update — September 23, 2026

Today's colorectal cancer research highlights